Coeptis Therapeutics (COEP) Competitors $9.51 +0.24 (+2.59%) Closing price 04:00 PM EasternExtended Trading$9.38 -0.14 (-1.42%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends COEP vs. VHAQ, ONCY, ANVS, SLS, RVPH, MURA, BYSI, IMRX, GBIO, and HOWLShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Viveon Health Acquisition (VHAQ), Oncolytics Biotech (ONCY), Annovis Bio (ANVS), SELLAS Life Sciences Group (SLS), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), BeyondSpring (BYSI), Immuneering (IMRX), Generation Bio (GBIO), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Viveon Health Acquisition Oncolytics Biotech Annovis Bio SELLAS Life Sciences Group Reviva Pharmaceuticals Mural Oncology BeyondSpring Immuneering Generation Bio Werewolf Therapeutics Viveon Health Acquisition (NYSE:VHAQ) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Does the media prefer VHAQ or COEP? In the previous week, Viveon Health Acquisition's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score. Company Overall Sentiment Viveon Health Acquisition Neutral Coeptis Therapeutics Neutral Do analysts prefer VHAQ or COEP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viveon Health Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of VHAQ or COEP? 22.1% of Viveon Health Acquisition shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 75.3% of Viveon Health Acquisition shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer VHAQ or COEP? Coeptis Therapeutics received 5 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformViveon Health AcquisitionN/AN/ACoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Which has higher valuation & earnings, VHAQ or COEP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViveon Health AcquisitionN/AN/A-$610KN/AN/ACoeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.65 Which has more risk & volatility, VHAQ or COEP? Viveon Health Acquisition has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Is VHAQ or COEP more profitable? Viveon Health Acquisition's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viveon Health AcquisitionN/A N/A N/A Coeptis Therapeutics N/A -1,094.50%-219.97% SummaryViveon Health Acquisition beats Coeptis Therapeutics on 6 of the 8 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.93M$2.99B$5.37B$9.09BDividend YieldN/A1.89%5.37%4.00%P/E Ratio-1.6544.7186.7617.45Price / SalesN/A292.961,278.6077.80Price / CashN/A189.5236.6032.90Price / Book19.913.974.924.62Net Income-$21.27M-$40.99M$117.96M$224.76M7 Day Performance15.96%2.73%2.19%2.84%1 Month Performance237.63%0.10%3.21%4.81%1 Year Performance-13.14%-0.75%26.71%21.17% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.4802 of 5 stars$9.51+2.6%N/A-15.7%$22.82MN/A-1.642VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002ONCYOncolytics Biotech1.3705 of 5 stars$0.83-4.8%$4.00+383.0%-34.6%$66.27MN/A-3.0730ANVSAnnovis Bio2.2648 of 5 stars$4.79-2.0%$31.40+555.5%-57.1%$66.09MN/A-1.073SLSSELLAS Life Sciences Group0.1965 of 5 stars$0.91-4.1%N/A+101.3%$64.28M$1M-1.3210Gap UpRVPHReviva Pharmaceuticals3.8045 of 5 stars$1.92+2.1%$11.25+486.0%-56.9%$64.20MN/A-1.735Analyst ForecastOptions VolumeGap UpMURAMural Oncology3.3134 of 5 stars$3.75-3.6%$16.00+326.7%-4.3%$63.83MN/A-0.41119Positive NewsGap DownBYSIBeyondSpringN/A$1.63-1.8%N/A+95.0%$63.62M$1.88M0.0080Positive NewsGap DownIMRXImmuneering3.6686 of 5 stars$2.04-1.4%$12.80+527.5%-65.8%$63.34M$320,000.00-1.0460Gap UpGBIOGeneration Bio4.213 of 5 stars$0.93+0.9%$6.50+595.9%-45.2%$62.39M$18.58M-0.43150Positive NewsGap UpHOWLWerewolf Therapeutics2.8975 of 5 stars$1.36-1.4%$12.00+782.4%-68.6%$60.61M$3.39M-0.8940Short Interest ↑Positive NewsGap Down Related Companies and Tools Related Companies Viveon Health Acquisition Alternatives Oncolytics Biotech Alternatives Annovis Bio Alternatives SELLAS Life Sciences Group Alternatives Reviva Pharmaceuticals Alternatives Mural Oncology Alternatives BeyondSpring Alternatives Immuneering Alternatives Generation Bio Alternatives Werewolf Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COEP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
